Updated advice regarding capillary leak syndrome
An extremely rare relapsing-remitting condition known as capillary leak syndrome has been reported overseas following vaccination with COVID-19 AstraZeneca. The syndrome results in fluid leaking from capillaries (small blood vessels) into surrounding tissue and can lead to severe organ damage or death if left untreated.
In two of the reported cases there was a previous history of capillary leak syndrome. As triggers for relapse are not well understood, the manufacturer of COVID-19 AstraZeneca has updated the 产品信息 advising it is not recommended that the vaccine be administered to people with a history of capillary leak syndrome. Individuals with a history of capillary leak syndrome should be referred to their closest VicSIS clinic for further assessment.
For further information refer to the following link:
TGA: COVID-19 weekly safety report
Updated immunisation reference page: Needle phobia
We have recently updated our Needle phobia page to include the latest information and resources available for addressing needle phobia.
Our page includes information and strategies for health care providers, individuals and care givers to manage needle phobia and immunisation.
To view this page, please click on the following link:
Healthed Webcast: Covid Update
Healthed will be hosting a webinar for healthcare professionals on Tuesday 20 July featuring a panel of expert speakers including MVEC’s A/Prof Nigel Crawford. This Covid update will cover the following topics:
- AZ confusion
- Delta crisis
- 心肌炎
- Boosters
- Pregnancy
- Variants
有关注册的更多信息和详细信息，请访问以下链接：
Healthed Webcast: Covid Update
Primary care approach to thrombosis with thrombocytopenia syndrome after COVID-19 AstraZeneca vaccine
The Australian Government Department of Health have published a new resource for healthcare providers in primary care to identify and manage 血栓形成伴血小板减少综合征 (TTS) after COVID-19 AstraZeneca.
To read the document in full, please refer to the following link:
ATAGI statement on use of COVID-19 vaccines in an outbreak setting
ATAGI have reviewed their COVID-19 vaccine advice and provided updated recommendations for significant COVID-19 outbreaks involving the Delta strain.
- ATAGI reinforces the recommendation for immunisation of those aged ≥ 60 years with COVID-19 AstraZeneca, with the benefits of vaccination strongly outweighing the risks.
- Vaccination of priority groups (eg. healthcare workers, disability and aged care workers, older people and those with medical risk factors) should be supported.
- Where supply of Comirnaty™ is constrained, adults under 60 years of age should reassess the benefits to them and their contacts from being vaccinated with COVID-19 AstraZeneca, versus the very rare risk of side effects.
- Additional unallocated supplies of any COVID-19 vaccine should be prioritised to populations in the areas of greatest risk of COVID-19 disease.
- In outbreak situations, the preferred interval between doses of COVID-19 AstraZeneca is 4-8 weeks. The recommended interval betweeen doses in a non-outbreak setting remains 12 weeks.
- Recommendations around the use of Comirnaty™ in an outbreak setting remain unchanged.
To read the statement in full, please click on the link below:
ATAGI statement on use of COVID-19 vaccines in an outbreak setting
SAEFVIC Rapid report: a new reporting pathway for COVID-19 vaccine AEFI
Reporting adverse events following immunisation (AEFI) is not mandatory in Victoria, however doing so allows the rapid investigation of any potential vaccine or system problems. This helps to ensure a safe and effective immunisation program and it maintains community confidence in vaccines.
The new SAEFVIC Rapid reporting pathway has been launched for reporting any common or expected side effects following a COVID-19 vaccine. Reporting via this pathway will not result in follow up of clinical symptoms however it will contribute to data collection and assist health authorities to understand the frequency of symptoms occurring. Should the vaccinee experience significant side effects, completing the SAEFVIC Extended report is recommended.
For more information on SAEFVIC, symptoms that should be reported, and instructions on how to report, please visit our immunisation reference page below:
MVEC: Surveillance of Adverse Events Following Vaccination in the Community (SAEFVIC)
ATAGI: Statement on the clinical use of zoster vaccines in older adults in Australia
There are 2 vaccines available for use within Australia to prevent the development of herpes zoster (shingles).
Zostavax is a live-attenuated vaccine and is funded on the National Immunisation Program (NIP) for immunocompetent adults aged 70 years and over.
Shingrix is a non-live vaccine. It is the preferred vaccine for those aged over 50 years due to a higher efficacy. It is currently only available for private purchase and availability is limited.
ATAGI have released a statement informing the use both vaccines. To read the statement in full please follow the link below:
ATAGI: Statement on the clinical use of zoster vaccines in older adults in Australia
The Conversation: Let’s hold off vaccinating children and teens against COVID-19. Prioritising adults is our best shot for now
Some countries who have successfully vaccinated a high proportion of their adult population are now shifting the focus of their COVID-19 vaccine rollout towards children and adolescents.
The following article reviews various international vaccine strategies for the younger population, and explores COVID-19 vaccine safety, including expected vaccine side effects and reports of myocarditis and pericarditis in adolescents. It looks at the potential impact that vaccination of children could have on transmission, herd immunity and keeping schools open.
The World Health Organization (WHO) recognises that globally the vaccine rollout has been slow and inequitable. Low income countries have insufficient vaccine supplies to protect high-priority groups.
In Australia where rates of COVID-19 community transmission is low, it is important that efforts remain on maximising vaccine coverage for adults and those who are at highest risk of severe COVID-19 disease.
要了解更多信息，请点击以下链接：
Australia's COVID-19 vaccine coverage update- July 5 2021
The Australian Government Department of Health continue to publish information relating to the COVID-19 vaccine rollout; including data on population coverage.
Latest figures show that 71.64% of Victorians aged 70 years and over have received their first dose of COVID-19 vaccine, with 16% having completed both recommended doses.
To view these statistics and read other information relating to vaccine distribution and uptake, please refer to:
Australian Government Department of Health: Australia's COVID-19 vaccine rollout
MVEC Animation: Thrombosis with Thrombocytopenia Syndrome (TTS) explained
MVEC have created a new animation to help to explain Thrombosis with Thrombocytopenia Syndrome (TTS), a rare and newly identified syndrome which has been reported in people who have received adenoviral vector COVID-19 vaccines such as COVID-19 AstraZeneca and the Johnson & Johnson/Janssen COVID-19 vaccine. This short animation helps to describe what it is, who is at risk and how TTS is diagnosed.
To view the animation and to find out more information on TTS please refer to our immunisation reference page:
MVEC: Thrombosis with Thrombocytopenia